# US 2015/0148539 A1 · Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148539 A1
- Document ID: US20150148539A1
- Status: Published application
- Kind: A1
- Application number: 14/603,556
- Filed: 2015-01-23
- Published: 2015-05-28
- Earliest claimed: 2009-03-30
- Assignees: TransTech Pharma, Inc.
- Applicants: TransTech Pharma, LLC
- Inventors: Adnan M.M. Mjalli; Christopher Behme; Daniel P. Christen; Devi Reddy Gohimukkula; Dharma Rao Polisetti; James C. Quada, JR.; Jennifer L.R. Freeman; Muralidhar Bondlela; Mustafa Guzel; Ravindra Reddy Yarragunta; Robert Carl Andrews; Santhosh Kalpathy; Stephen Thomas Davis; Thomas Scott Yokum
- Web page: https://patentgrep.com/patent/US20150148539A1

## CPC

- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/02: for peripheral neuropathies
- A61P 27/02: Ophthalmic agents
- C07D 319/20: with substituents attached to the hetero ring
- C07D 491/06: Peri-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to substituted azoanthracene derivatives and intermediates for the preparation thereof. The substituted azoanthracene derivatives and associated intermediates may be useful for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, disorders, and conditions wherein modulation of the human GLP-1 receptor is beneficial.

## Claims

### Claim 1

A compound of the formula:
wherein
R1 is hydrogen or methyl, and
R2 is —CO2-tert-butyl, or -1-(phenyl)-propyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R2 is —(R)-1-phenyl-propyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R2 is —(S)-1-phenyl-propyl.

### Claim 4

A compound of the formula:
wherein
R1 is methyl, and
R2 is hydrogen or —CO2-tert-butyl.

### Claim 5

A compound of the formula:
wherein
R1 is methyl, and
R2 is —CO2-tert-butyl or -1-(phenyl)-propyl.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R2 is —(R)-1-phenyl-propyl.

### Claim 7 (depends on 5)

The compound of claim 5, wherein R2 is —(S)-1-phenyl-propyl.

### Claim 8

A compound of the formula:
wherein
R1 is methyl, and
R2 is -1-(phenyl)-propyl.

### Claim 9 (depends on 8)

The compound of claim 8, wherein R2 is —(R)-1-phenyl-propyl.

### Claim 10 (depends on 8)

The compound of claim 8, wherein R2 is —(S)-1-phenyl-propyl.

### Claim 11

A compound of the formula:
